Alice Mims, MD

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

July 20th 2018

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).